Key facts
- This page summarizes Peter Cicala's Form 4 filing for Eterna Therapeutics Inc. (ERNA).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 10 Feb 2025, 19:00.
Peter Cicala - 07 Feb 2025 Form 4 Insider Report for Eterna Therapeutics Inc. (ERNA)
- Form type
- 4
- Accepted by SEC
- 10 Feb 2025, 19:00:08 UTC
- Previous filing
- 29 Apr 2024
- SEC filing
- View on sec.gov
- Reporting owner signature
- /s/ Peter Cicala
Source evidence
4 source fields
Reporting owner
1 detail
Key filing fact
Peter Cicala filed Form 4 for Eterna Therapeutics Inc. (ERNA) on 10 Feb 2025.
Change
- Previous filing in this sequence was filed on 29 Apr 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ERNA
transaction
Derivative
Stock Option (Right to buy)
Award
- Transaction value
- $0
- Shares
- +51,485
- Change %
- Price
- $0.000000
- Shares after
- 51,485
- Date
- 07 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 51,485
- Exercise price
- $0.3400
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Subject to continued service, one-third of the shares underlying the stock option will vest on the first anniversary of the grant date, and the remaining shares underlying the stock option will vest in 24 substantially equal monthly installments thereafter.